



Figure S2. Waterfall plot depicting tumor responses assessed by RECIST criteria per blinded independent review committee in the efficacy evaluable population. Maximum change in sum of target lesions in 71 evaluable patients (1 patient did not have a post-baseline assessment for the target lesion in the central review dataset; therefore, this patient is excluded from the BIRC waterfall plot). RECIST, Response Criteria in Solid Tumors; VEGFRi, vascular endothelial growth factor receptor inhibitor.